Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice

武装溶瘤 HSV 载体在同基因小鼠中诱导抗 GBM 免疫反应

基本信息

项目摘要

Oncolytic HSV vectors (oHSV) offer considerable promise in the treatment of Glioblastoma Multiforme (GBM). In previous studies we designed a new base vector (KGN-4:T124) that is blocked for replication in normal brain tissue by brain-specific cellular miR-124 targeting of ICP4 expression. This base vector was further retargeted (KGNE-4:T124) to achieve selective infection of GBM cells expressing EGFR/EGFRvIII. Arming of this vector with a matrix metalloproteinase (KGNE-4:T124-MMP9) enhanced vector spread and oncolysis in xenogeneic animal models. However, virolysis alone is unlikely to achieve complete elimination of tumor cells that can cause recurrence. Effective elimination of all tumor cells will require the induction of innate and adaptive anti-tumor immunity. Unfortunately, GBM down-regulates the cellular machinery needed to sustain activation of immune cells including NK, macrophages and cytotoxic T cells. Therefore we propose to test the hypothesis that GBM treatment with our oHSV base vectors, KGN-4:T124 and KGNE-4:T124, can be enhanced through vector arming with immunomodulatory genes that inhibit tumor progression and induce innate and adaptive anti-tumor immune responses. To this end, we will initially exploit a tumor cell line (BAGL1) derived from a GBM tumor induced in BALB/c mice by Sleeping Beauty transposition of genes encoding luciferase, anti-p53 shRNA, N-RasV12 and human EGFRvIII. These experiments will be extended to a genetically-induced GBM model developed by Dr. Eric Holland that avoids tumor cell injection. Our aims will seek to counteract three aspects of immune evasion in GBM: (i) ADAM17-mediated shedding of NK cell activators and reduced NK function, (ii) expression of the immune checkpoint molecules that lead to NK and T cell exhaustion, and (iii) the presence of M2 macrophages that contribute to an immunosuppressive tumor microenvironment (TME). In Aim 1, we will test the hypothesis that our unarmed base vectors, collectively referred to as KGN(E)-4:T124, will provide an effective GBM treatment in immune competent mice. We will determine the impact of vector dosing on intratumoral vector distribution, TME composition and animal survival, and assess the value of EGFR targeting. We will also examine the effect of prior HSV immunization on treatment outcomes. In Aim 2, we will test the hypothesis that KGN(E)- 4:T124 derivatives armed with TIMP-3 (ADAM17 inhibitor/VEGF-R2 antagonist) will improve therapy. We will evaluate the impact of TIMP-3 expression on NK cell activation, tumor spread and animal survival. In Aim 3, we will test the hypothesis that vectors armed with single chain antibody (scFv) checkpoint inhibitors (anti-PD-L1 or anti-CTLA4), alone or in combination with depletion of the immunosuppressive (M2) TAM population using BLZ945-mediated inhibition of colony-stimulating factor-1 receptor (CSF-1R), will produce effective anti-tumor immunity, particularly in HSV immune mice. Anti-tumor immunity will be established using a bi-lateral tumor model and confirmed by selective antibody-mediated T cell depletion.
溶瘤HSV载体(oHSV)在多形性胶质母细胞瘤(GBM)的治疗中提供了相当大的希望。 在以前的研究中,我们设计了一个新的基础载体(KGN-4:T124),该载体在正常脑中被阻断复制 通过脑特异性细胞miR-124靶向ICP 4表达,这个基础载体被进一步重新定位 (KGNE-4:T124)以实现表达EGFR/EGFRvIII的GBM细胞的选择性感染。准备好这个向量 基质金属蛋白酶(KGNE-4:T124-MMP 9)增强载体在异种细胞中的扩散和溶瘤作用 动物模型然而,单独的病毒裂解不太可能实现肿瘤细胞的完全消除, 复发有效消除所有肿瘤细胞将需要诱导先天性和适应性抗肿瘤 免疫力不幸的是,GBM下调了维持免疫激活所需的细胞机制。 细胞,包括NK、巨噬细胞和细胞毒性T细胞。因此,我们建议测试假设,GBM 用我们的oHSV基础载体KGN-4:T124和KGNE-4:T124的治疗可以通过载体武装来增强 具有抑制肿瘤进展并诱导先天性和适应性抗肿瘤免疫的免疫调节基因 应答为此,我们将首先利用来源于GBM肿瘤的肿瘤细胞系(BAGL 1),该肿瘤细胞系是在GBM中诱导的。 BALB/c小鼠通过睡美人转座编码荧光素酶、抗p53 shRNA、N-RasV 12和 人EGFRvIII。这些实验将扩展到由Dr. 埃里克·霍兰德避免了肿瘤细胞注射。我们的目标将寻求对抗免疫逃避的三个方面 在GBM中:(i)ADAM 17介导的NK细胞活化剂脱落和NK功能降低,(ii) 导致NK和T细胞耗竭的免疫检查点分子,以及(iii)M2巨噬细胞的存在 这有助于免疫抑制肿瘤微环境(TME)。在目标1中,我们将检验假设 我们的非武装基础载体,统称为KGN(E)-4:T124,将提供有效的GBM 在免疫活性小鼠中的治疗。我们将确定载体给药对肿瘤内载体的影响。 分布、TME组成和动物存活率,并评估EGFR靶向的价值。我们亦会研究 既往HSV免疫对治疗结果的影响。在目标2中,我们将检验KGN(E)- 4:装备有TIMP-3(ADAM 17抑制剂/VEGF-R2拮抗剂)的T124衍生物将改善治疗。我们将 评估TIMP-3表达对NK细胞活化、肿瘤扩散和动物存活的影响。在目标3中,我们 将检验装备有单链抗体(scFv)检查点抑制剂(抗PD-L1或抗PD-L2)的载体的假设。 抗-CTLA 4),单独或与免疫抑制性(M2)TAM群体的消耗组合, BLZ 945介导的抑制集落刺激因子-1受体(CSF-1 R),将产生有效的抗肿瘤作用 免疫,特别是在HSV免疫小鼠中。将使用双侧肿瘤建立抗肿瘤免疫 模型,并通过选择性抗体介导的T细胞耗竭证实。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph C Glorioso其他文献

EFFECTS OF HERPES SIMPLEX VIRUS VECTOR-MEDIATED ENKEPHALIN GENE THERAPY ON BLADDER OVERACTICITY AND NOCICEPTION
  • DOI:
    10.1016/s0022-5347(09)60069-0
  • 发表时间:
    2009-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Hitoshi Yokoyama;Chikashi Saitoh;Minoru Miyazato;Osamu Nishizawa;Michael B Chancellor;William F Goins;James R Goss;Joseph C Glorioso;Naoki Yoshimura
  • 通讯作者:
    Naoki Yoshimura
EFFECTS OF DIFFERENT ENKEPHALIN TREATMENTS ON BLADDER PAIN
  • DOI:
    10.1016/s0022-5347(08)60177-9
  • 发表时间:
    2008-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Hitoshi Yokoyama;Chikashi Saitoh;Minoru Miyazato;Osamu Nishizawa;Michael B Chancellor;William F Goins;James R Goss;Joseph C Glorioso;Naoki Yoshimura
  • 通讯作者:
    Naoki Yoshimura
871 EFFECT OF HERPES SIMPLEX VIRUS (HSV) VECTOR-MEDIATED INTERLEUKIN 4 GENE THERAPY ON ENHANCED BLADDER PAIN BEHAVIOR IN RATS WITH CYCLOPHOSPHAMIDE (CYP)-INDUCED CYSTITIS
  • DOI:
    10.1016/j.juro.2013.02.440
  • 发表时间:
    2013-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tomohiko Oguchi;Hitoshi Yokoyama;Yasuhito Funahashi;Osamu Nishizawa;Satoru Yoshikawa;William F Goins;James R Goss;Joseph C Glorioso;Naoki Yoshimura
  • 通讯作者:
    Naoki Yoshimura
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
用于基因治疗的病毒载体:将感染因子转化为治疗载体的艺术
  • DOI:
    10.1038/83324
  • 发表时间:
    2001-01-01
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Mark A. Kay;Joseph C Glorioso;Luigi Naldini
  • 通讯作者:
    Luigi Naldini

Joseph C Glorioso的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph C Glorioso', 18)}}的其他基金

Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice
武装溶瘤 HSV 载体在同基因小鼠中诱导抗 GBM 免疫反应
  • 批准号:
    9927607
  • 财政年份:
    2018
  • 资助金额:
    $ 38.92万
  • 项目类别:
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM
项目 1:武装溶瘤 HSV 载体以改善 GBM 同基因小鼠模型中的病毒溶解
  • 批准号:
    10019362
  • 财政年份:
    2013
  • 资助金额:
    $ 38.92万
  • 项目类别:
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM
项目 1:武装溶瘤 HSV 载体以改善 GBM 同基因小鼠模型中的病毒溶解
  • 批准号:
    10491206
  • 财政年份:
    2013
  • 资助金额:
    $ 38.92万
  • 项目类别:
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM
项目 1:武装溶瘤 HSV 载体以改善 GBM 同基因小鼠模型中的病毒溶解
  • 批准号:
    10251082
  • 财政年份:
    2013
  • 资助金额:
    $ 38.92万
  • 项目类别:
Project 1: Treatment of GBM using an oncolytic HSV engineered to improve immunogenic tumor destruction
项目 1:使用经过改造的溶瘤 HSV 治疗 GBM,以改善免疫原性肿瘤破坏
  • 批准号:
    10712280
  • 财政年份:
    2013
  • 资助金额:
    $ 38.92万
  • 项目类别:
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling
感觉传入中甘氨酸受体的表达调节疼痛信号传导
  • 批准号:
    8309978
  • 财政年份:
    2011
  • 资助金额:
    $ 38.92万
  • 项目类别:
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling
感觉传入中甘氨酸受体的表达调节疼痛信号传导
  • 批准号:
    8186007
  • 财政年份:
    2011
  • 资助金额:
    $ 38.92万
  • 项目类别:
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling
感觉传入中甘氨酸受体的表达调节疼痛信号传导
  • 批准号:
    8703184
  • 财政年份:
    2011
  • 资助金额:
    $ 38.92万
  • 项目类别:
Glycine Receptor Expression in Sensory Afferents to Modulate Pain Signaling
感觉传入中甘氨酸受体的表达调节疼痛信号传导
  • 批准号:
    8520405
  • 财政年份:
    2011
  • 资助金额:
    $ 38.92万
  • 项目类别:
Functional Genomic Studies of Early Myogenic Differentiation
早期肌源分化的功能基因组研究
  • 批准号:
    7663827
  • 财政年份:
    2008
  • 资助金额:
    $ 38.92万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了